luspatercept,epoetin alfa
bms
['commands', 'lusp', 'commands trial', 'commands,(-recommands)']
results of the commands trial just presented at #asco23: luspatercept poised to become a new first-line soc for transfusion-dependent, lower-risk myelodysplastic syndromes: #ascodailynews #hemeonc 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.